Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.48 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.39 |
| ▸ | TCF4 | P15884 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641704 | 0.91 | LOXL2 (0.47) | LOXL2SLC7A5CYP4F2CYP4A11CASR | |
| SCHEMBL3343678 | 0.90 | LOXL2 (0.50) | LOXL2SLC7A5CYP4F2CYP4A11CASR | |
| SCHEMBL3344191 | 0.84 | CASR (0.42) | LOXL2GPR17SLC7A5CYP4F2CYP4A11 | |
| SCHEMBL3341254 | 0.81 | GPR17 (0.42) | LOXL2GPR17SLC7A5CYP4F2CYP4A11 | |
| SCHEMBL13305156 | 0.81 | GPR17 (0.42) | LOXL2GPR17SLC7A5CYP4F2CYP4A11 | |
| SCHEMBL3346867 | 0.81 | TRPM8 (0.42) | LOXL2SLC7A5CYP4F2CYP4A11ADRB2 | |
| SCHEMBL3639396 | 0.79 | GAA (0.47) | — | |
| SCHEMBL3340741 | 0.78 | GPR17 (0.50) | LOXL2GPR17SLC7A5CYP4F2CYP4A11 | |
| SCHEMBL3643578 | 0.76 | CASR (0.42) | LOXL2SLC7A5CYP4F2CYP4A11CASR | |
| SCHEMBL8143043 | 0.75 | LMNA (0.62) | CASRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160424-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| WO-2008156817-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160424-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | LOXL2 2685/4885GPR17 2943/4885SLC7A5 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.